Evaluation of Spliceosome Protein SmD2 as a Potential Target for Cancer Therapy
Jing Li, Peiyu Li, Tereza Brachtlova, Ida H. van der Meulen-Muileman, Henk Dekker, Vishal S. Kumar, Marieke Fransen, Idris Bahce, Emanuela Felley-Bosco, Victor W. van Beusechem · 2024
Read Evaluation of Spliceosome Protein SmD2 as a Potential Target for Cancer Therapy by Jing Li, Peiyu Li, Tereza Brachtlova, Ida H. van der Meulen-Muileman, Henk Dekker, Vishal S. Kumar, Marieke Fransen, Idris Bahce, Emanuela Felley-Bosco, Victor W. van Beusechem (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11642717.txt.
Description
Jing Li and nine co-authors evaluate in 2024 whether a splicing protein called SmD2 makes a good target for cancer drugs. Splicing machinery edits RNA messages, and tumors often lean hard on it. The gene behind SmD2 is switched on at high levels in nearly all of 26 solid tumor types studied.
Silencing the gene killed cancer cells from many sources while sparing most normal cells, marking it as a cancer-selective lethal target. Public cell-line data agreed. Genes with similar kill profiles pointed to a web of RNA handling and protein production steps that tumors cannot afford to lose together. The work nominates SmD2 for drug development and maps partner targets that might deepen the effect.
Catalog record
| CREATOR | Jing Li, Peiyu Li, Tereza Brachtlova, Ida H. van der Meulen-Muileman, Henk Dekker, Vishal S. Kumar, Marieke Fransen, Idris Bahce, Emanuela Felley-Bosco, Victor W. van Beusechem |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |